




Cornelius Pompe (Autor)  
**Development of New *In-Situ* Hardening and Bioactivated Composite Materials for Orthopedic Indications**



<https://cuvillier.de/de/shop/publications/1315>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany  
Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>

---

## Table of Contents

<b>1.</b>	<b>Introduction .....</b>	<b>1</b>
1.1	Bone Morphogenetic Proteins .....	1
1.1.1	From historic perspective .....	1
1.1.2	Biochemistry .....	2
1.1.3	BMP receptor signaling .....	4
1.1.4	Biologic activity and osteoinduction.....	5
1.2	State of the art in bone growth factor delivery .....	6
1.2.1	Demands on potential bone substitutes.....	6
1.2.2	Applied materials.....	7
1.2.2.1	Natural polymers.....	8
1.2.2.2	Synthetic polymers .....	8
1.2.2.3	Inorganic materials .....	10
1.2.2.4	Composite materials in bone augmentation .....	11
1.2.2.5	The way to injectable delivery systems for bone morphogenetic proteins .....	13
<b>2.</b>	<b>Development of an <i>In-Situ</i> Hardening Bone Substitute for Minimal Invasive Surgery .....</b>	<b>16</b>
2.1	Objectives .....	16
2.2	Materials and Methods .....	18
2.2.1	Materials .....	18
2.2.1.1	RhGDF-5.....	18
2.2.1.2	Antibodies used within the scope of rhGDF-5 quantification.....	18
2.2.1.3	Biodegradable polymers .....	18
2.2.1.4	Additional materials .....	19
2.2.1.5	Other excipients .....	21
2.2.1.6	Buffer components.....	21
2.2.1.7	Reagents and other substances.....	22

2.2.2	Methods .....	23
2.2.2.1	Phase transition of $\beta$ -tricalcium phosphate ( $\beta$ -TCP).....	23
2.2.2.2	Biocement D powder preparation .....	23
2.2.2.2	IFS preparation .....	23
2.2.2.4	Sample incubation in PBS .....	24
2.2.2.5	Mechanical testing .....	24
2.2.2.6	Vacuum drying of incubated specimens.....	25
2.2.2.7	Differential scanning calorimetry (DSC) .....	25
2.2.2.8	Light microscopy and software based quantification of superficial pores .....	25
2.2.2.9	Scanning electron microscopy (SEM) .....	26
2.2.2.10	Micro computed tomography ( $\mu$ CT).....	26
2.2.2.11	X-ray powder diffraction (XRD).....	26
2.2.2.12	Karl Fischer titration.....	26
2.2.2.13	Size exclusion chromatography with coupled multi angle laser light scattering and differential refractive index detection (SEC-MALLS-DRI).....	27
2.2.2.14	Drying of rhGDF-5 containing preparations.....	28
2.2.2.15	Incubation of rhGDF-5 coated $\alpha$ -TCP with various organic plasticizers.....	28
2.2.2.16	Photometric quantification of oxidative species in organic plasticizers .....	28
2.2.2.17	RhGDF-5 extraction after incubation with organic plasticizers.....	28
2.2.2.18	RP-HPLC .....	29
2.2.2.19	LC-ESI-MS.....	29
2.2.2.20	RhGDF-5 release from IFS.....	30
2.2.2.21	Determination of rhGDF-5 release from IFS by ELISA .....	30
2.3	Results and Discussion .....	31
2.3.1	Improvement of the mechanical performance of the IFS .....	31
2.3.1.1	Investigations on the inorganic filler .....	31
2.3.1.2	Optimizing the polymer/cement ratio .....	38
2.3.1.3	Variation of the organic plasticizer.....	40
2.3.1.4	Variation of the polymer component.....	46
2.3.2	Modification of surface morphology .....	50
2.3.2.1	Screening of potential pore forming agents.....	50
2.3.2.2	The impact of NaCMC particle size on pore formation.....	58
2.3.2.3	The impact of the degree of substitution of NaCMC on pore formation .....	61
2.3.2.4	The impact of NaCMC viscosity on pore formation .....	63
2.3.2.5	Conclusion .....	64
2.3.3	The influence of the inorganic filler on rhGDF-5 release.....	64

---

2.3.4	PLGA stability within the IFS .....	67
2.3.4.1	Purpose.....	67
2.3.4.2	The impact of post-manufacturing vacuum drying on different IFS formulations .....	67
2.3.4.3	Evaluation of different drying procedures for PEG 400 .....	68
2.3.4.4	Shelf life study of different IFS formulations .....	69
2.3.5	<i>In-vitro</i> biodegradation of the IFS .....	78
2.3.6	Compatibility of rhGDF-5 with various organic plasticizers .....	83
2.3.6.1	Solvent screening .....	83
2.3.6.2	Investigations on degradation pathways .....	84
2.3.6.3	Approaches to reduce rhGDF-5 oxidation .....	91
2.3.6.4	Conclusion .....	93
2.4	Summary.....	94
<b>3.</b>	<b>A new “putty-like” <i>in-situ</i> hardening composite material .....</b>	<b>98</b>
3.1	Introduction .....	98
3.2	Materials and Methods .....	100
3.2.1	Materials .....	100
3.2.1.1	RhGDF-5.....	100
3.2.1.2	Antibodies used within the scope of rhGDF-5 quantification.....	100
3.2.1.3	RhBMP-2 ( <i>E.coli</i> ) .....	100
3.2.1.4	Antibodies used within the scope of rhBMP-2 ( <i>E.coli</i> ) quantification .....	100
3.2.1.5	RhBMP-2 ( <i>CHO</i> ).....	101
3.2.1.6	Biodegradable polymers .....	101
3.2.1.7	Other excipients .....	101
3.2.1.8	Buffer components.....	102
3.2.1.9	Used buffers.....	103
3.2.1.10	Other reagents and substances .....	104
3.2.2	Methods .....	107
3.2.2.1	CDP1c/CDP2c putty fluid preparation .....	107
3.2.2.2	CDP1c/CDP2c preparation.....	108
3.2.2.3	PEG 400 staining .....	108

3.2.2.4	Incubation of CDP1c in PBS.....	109
3.2.2.5	Vacuum drying of incubated specimens.....	109
3.2.2.6	Differential scanning calorimetry (DSC) .....	109
3.2.2.7	SEM/EDX analysis.....	109
3.2.2.8	Micro computed tomography ( $\mu$ CT).....	110
3.2.2.9	Determination of PLGA molecular weight by SEC-MALLS-DRI.....	110
3.2.2.10	Sterilization by $\gamma$ -irradiation .....	110
3.2.2.11	CDP1/CDP2 preparation .....	111
3.2.2.12	Protein release from CDP1c/CDP2c for ELISA evaluation .....	111
3.2.2.13	Determination of rhGDF-5 release by ELISA .....	111
3.2.2.14	Determination of rhBMP-2 ( <i>E.coli</i> ) release in $\alpha$ -MEM/10% FCS by ELISA.....	111
3.2.2.15	Determination of rhBMP-2 ( <i>CHO</i> ) release in $\alpha$ -MEM/10% FCS by ELISA .....	112
3.2.2.16	Extraction from non released rhGDF-5 fractions from CDP1c .....	112
3.2.2.17	RhGDF-5 characterization and quantification by RP-HPLC.....	112
3.2.2.18	RhBMP-2 quantification by RP-HPLC .....	113
3.2.2.19	RhGDF-5 analysis by SEC .....	114
3.2.2.20	RhGDF-5 analysis by LDS-PAGE .....	114
3.2.2.21	RhGDF-5 analysis by IEF .....	114
3.2.2.22	RhGDF-5 release from CDP1c for ALP assay .....	115
3.2.2.23	Cultivation of murine stromal MCHT-1/26 cells .....	115
3.2.2.24	Preparation of murine stromal MCHT-1/26 cells for ALP assay.....	115
3.2.2.25	ALP assay.....	116
3.2.2.26	CDP1c biocompatibility study <i>in-vivo</i> .....	116
3.3	Results and Discussion .....	117
3.3.1	An <i>in-vitro</i> model for rhBMP-2 release from some CDP2c variants .....	117
3.3.1.1	Objectives .....	117
3.3.1.2	The impact of phosphate ion concentration on rhBMP-2 ( <i>E.coli</i> ) solubility .....	117
3.3.1.3	The impact of pH on rhBMP-2 ( <i>E.coli</i> ) solubility .....	119
3.3.1.4	RhBMP-2 ( <i>E.coli</i> ) release in an acetate/phosphate buffer based medium .....	120
3.3.1.5	Interaction between rhBMP-2 ( <i>E.coli</i> ) and $\beta$ -TCP .....	122
3.3.1.6	Investigations of rhBMP-2 ( <i>E.coli</i> ) release in MES buffered medium.....	123
3.3.1.7	Investigations of rhBMP-2 ( <i>E.coli</i> ) release in $\alpha$ -MEM/FCS based medium.....	125
3.3.1.8	Investigation of rhBMP-2 ( <i>CHO</i> ) release in MES buffered medium .....	127
3.3.1.9	Investigation of rhBMP-2 ( <i>CHO</i> ) release in $\alpha$ -MEM/FCS based medium .....	129
3.3.1.10	Conclusion .....	130
3.3.2	<i>In-vitro</i> biodegradation of CDP1c .....	131

---

3.3.2.1	Introduction .....	131
3.3.2.2	Molecular weight and mass loss .....	131
3.3.2.3	Thermal behavior .....	134
3.3.2.4	Residual PEG 400 content .....	136
3.3.2.5	Morphology .....	137
3.3.2.6	Conclusion .....	138
3.3.3	<i>In-vitro</i> rhGDF-5 release.....	139
3.3.3.1	Introduction .....	139
3.3.3.2	RhGDF-5 release from CDP1c .....	139
3.3.3.3	EDX analysis of CDP1c variants after 24 h of incubation in PBS .....	141
3.3.3.4	Visualization of phase inversion .....	143
3.3.3.5	SEM analysis CDP1c variants after 24 h of incubation in PBS .....	145
3.3.3.6	Conclusion .....	145
3.3.4	Characterization of non released rhGDF-5 fractions.....	146
3.3.4.1	Introduction .....	146
3.3.4.2	RP-HPLC of non released rhGDF-5 fractions .....	146
3.3.4.3	IEF of non released rhGDF-5 fractions.....	147
3.3.4.4	LDS-PAGE of non released fractions .....	148
3.3.4.5	SEC analysis of non released fractions.....	150
3.3.4.5	Alkaline phosphatase activity of released rhGDF-5 .....	151
3.3.4.6	Conclusion .....	153
3.3.5	Effects of sterilization on CDP1c putty fluid formulations .....	153
3.3.5.1	Introduction .....	153
3.3.5.2	The impact of $\gamma$ -irradiation on PLGA molecular weight .....	156
3.3.5.3	The impact of $\gamma$ -irradiation on rhGDF-5 release .....	163
3.3.5.4	Conclusion .....	166
3.3.6	Biocompatibility of CDP1c.....	168
3.4	Summary.....	169
<b>4.</b>	<b>Final Conclusion .....</b>	<b>172</b>
<b>5.</b>	<b>References.....</b>	<b>175</b>